Clinical trial · Observational
Breast Cancer Tumor Care Observational Programme
Breast Cancer Tumor Care Patient Observation Programme
NCT00660244CI-TRIAL-00007094completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to investigate efficacy and tolerability under anastrozole (Arimidex) treatment.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Arthralgia | — | UNRESOLVED | — |
| Post Menopausal | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| anastrozole | Drug | Anastrozole | ALIAS |
Design
Arms and outcomes
Arms (1)
- label
- 1
- interventionNames
- Drug: anastrozole
Primary outcomes (1)
- measure
- Progression of disease and tolerability in general
- timeFrame
- Baseline, every 3 month
Secondary outcomes (1)
- measure
- Patient questionnaire to collect data on Incidence, time of onset and treatment of arthralgia
- timeFrame
- Baseline, every 3 month
Eligibility
Eligibility (as posted)
- Sex
- Female
Show eligibility criteria text
Inclusion Criteria: * Postmenopausal women * Already on upfront Arimidex Therapy (Start 1-4 weeks before) * HR+ Exclusion Criteria: * Premenopausal women * Tamoxifen switch patients
References
Publications (0)
Data not yet available
No reference posted for this study.